Nykode Therapeutics Share Price OTC Markets
Stocks
VACBF
NO0010714785
Biotechnology & Medical Research
OTC Markets Traded|
Delayed
OTC Markets
15:35:30 11/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 0.3542 USD | +10.24% |
|
-.--% | +127.42% |
| 08-28 | Nykode Therapeutics Raises NOK286 Million via Share Placement | MT |
| 08-27 | ABG Sundal Collier raises the target price for Nykode Therapeutics to 7.0 Norwegian kroner (4.5), reiterates buy | FW |
| Market Cap | 1.34B 144M 124M 117M 107M 200M 13.62B 201M 1.39B 538M 6.96B 541M 530M 22.88B | P/E 2026 * |
-6.31x | P/E 2027 * | 84.7x |
|---|---|---|---|---|---|
| Enterprise Value | 858M 92.17M 79.52M 74.91M 68.25M 128M 8.71B 129M 887M 344M 4.45B 346M 339M 14.62B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | 3.4x |
| Free-Float |
56.4% | Yield 2026 * |
-
| Yield 2027 * | - |
| Markets | Quality | ||
|---|---|---|---|
Oslo Bors
| VACC | Real-time | |
CBOE
| Real-time | ||
|
Nasdaq Stockholm
| NYKD O | Delayed | |
|
OTC Markets
| VACBF | Delayed | |
|
Börse Stuttgart
| 5VB | Delayed | |
|
Boerse Muenchen
| 5VB | Real-time | |
|
Deutsche Boerse AG
| 5VB | Delayed | |
|
CBOE
| Real-time |
Last Transcript : Nykode Therapeutics
| 1 day | +10.24% | ||
| 1 month | +10.24% | ||
| 3 months | -6.79% | ||
| 6 months | -6.79% | ||
| Current year | +127.42% |
| 1 month | 0.35 |  | 0.35 |
| Current year | 0.31 | | 0.38 |
| 1 year | 0.16 | | 0.38 |
| 3 years | 0.16 | | 2.25 |
| 5 years | 0.16 | | 2.36 |
| 10 years | 0.16 | | 2.36 |
| Manager | Title | Age | Since |
|---|---|---|---|
Michael Engsig
CEO | Chief Executive Officer | 54 | 31/12/2018 |
| President | 49 | 31/12/2016 | |
Harald Gurvin
DFI | Director of Finance/CFO | 51 | 02/05/2021 |
| Director | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 54 | - | |
Trygve Lauvdal
BRD | Director/Board Member | 57 | - |
Susanne Stuffers
CHM | Chairman | 45 | 22/04/2025 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +10.24% | -.--% | - | - | 144M | |
| +1.03% | -2.05% | +39.28% | +94.60% | 68.87B | |
| +1.18% | +0.42% | +49.28% | +91.87% | 65.29B | |
| -0.29% | +3.82% | -12.17% | +377.93% | 27.65B | |
| +2.97% | -0.10% | +41.86% | +14.84% | 25.77B | |
| -1.13% | -8.08% | +1.97% | -16.07% | 26.08B | |
| +1.01% | +1.38% | +26.48% | -17.50% | 20.14B | |
| +3.45% | -14.83% | +225.22% | +389.50% | 17.03B | |
| +0.77% | -4.55% | -0.36% | +549.41% | 15.03B | |
| +1.22% | +7.17% | +60.23% | +165.92% | 14.5B | |
| Average | +2.04% | -2.66% | +47.98% | +183.39% | 31.15B | |
| Weighted average by Cap. | +1.06% | -2.12% | +42.63% | +142.21% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 210M 22.55M 19.46M 18.33M 16.7M 31.22M 2.13B 31.45M 217M 84.22M 1.09B 84.7M 82.84M 3.58B |
| Net income | -209M -22.5M -19.41M -18.29M -16.66M -31.15M -2.13B -31.38M -217M -84.03M -1.09B -84.51M -82.66M -3.57B | 9.97M 1.07M 924K 870K 793K 1.48M 101M 1.49M 10.3M 4M 51.71M 4.02M 3.93M 170M |
| Net Debt | -484M -52.02M -44.87M -42.27M -38.51M -71.99M -4.91B -72.53M -500M -194M -2.51B -195M -191M -8.25B | -628M -67.51M -58.24M -54.87M -49.99M -93.44M -6.38B -94.14M -650M -252M -3.26B -254M -248M -10.71B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- VACC Stock
- VACBF Stock
Select your edition
All financial news and data tailored to specific country editions
